291. Hirschsprung disease, entire colon type
13 clinical trials,   32 drugs   (DrugBank: 15 drugs),   0 gene,   0 pathway
Searched query = "Hirschsprung disease, entire colon type", "Hirschsprung disease, small intestine type", "Hirschsprung disease", "Hirschprung disease", "Hirschsprung disease associated entercolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000024993 | 2016/12/01 | 15/12/2016 | Study for efficacy of usage of enteral nutrient with immuno-balance modulation action in perioperative management of pediatric patients | Hirschsprung's disease, Atresia ani, Congenital biliary dilatation, GERD | In the control group, the following enteral nutrient will be administered (breast milk or artificial milk for infants, Racol for infants). Dose and duration: Before surgery, the patient will take enteral nutrients at 60 to 100 kcal / kg per day for 3 days. After the surgery, enteral nutrition will restart within 2 to 3 days after surgery, and continue until 6th postoperative day. In contrast, immunomodulatory nutrition is administered in the test group. Dose and duration: Before surgery, the patient will take enteral nutrients at 60 to 100 kcal / kg per day for 3 days. After the surgery, enteral nutrition will restart within 2 to 3 days after surgery, and continue until 6th postoperative day. The study period is from December 1, 2016 to March 31, 2018. | University of Tsukuba Hospital | NULL | Pending | 6months-old | 48months-old | Male and Female | 10 | Not applicable | Japan |